Wealthfront Advisers LLC Purchases Shares of 76,210 Boston Scientific Corporation $BSX

Wealthfront Advisers LLC acquired a new stake in Boston Scientific Corporation (NYSE:BSX) in the second quarter, HoldingsChannel reports. The fund acquired 76,210 shares of the medical equipment provider’s stock, valued at approximately $3,253,000.

Several other institutional investors also recently modified their holdings of BSX. Kelleher Financial Advisors acquired a new stake in Boston Scientific in the 2nd quarter valued at about $25,000. FWL Investment Management LLC bought a new position in Boston Scientific during the second quarter worth about $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific during the fourth quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC bought a new stake in Boston Scientific in the fourth quarter valued at approximately $26,000. Finally, Clal Insurance Enterprises Holdings Ltd bought a new stake in Boston Scientific in the first quarter valued at approximately $28,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BSX has been the subject of several research analyst reports. Daiwa Securities Group downgraded Boston Scientific from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. BTIG Research dropped their price target on Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, July 29th. Citigroup reduced their price objective on shares of Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Jefferies Financial Group dropped their price objective on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday, June 24th. Finally, Leerink Partners set a $60.00 target price on shares of Boston Scientific in a research note on Thursday, July 30th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig purchased 5,000 shares of the stock in a transaction that occurred on Friday, July 31st. The shares were acquired at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director owned 30,359 shares in the company, valued at $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David C. Habiger acquired 2,100 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was acquired at an average price of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders have acquired 194,522 shares of company stock worth $9,385,210. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Stock Performance

BSX opened at $49.47 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The business has a fifty day simple moving average of $46.26 and a 200 day simple moving average of $57.91. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The company has a market capitalization of $71.69 billion, a PE ratio of 20.03, a price-to-earnings-growth ratio of 1.13 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter last year, the business earned $0.75 EPS. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts expect that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its Board of Directors has initiated a share buyback program on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.